Facing strong opposition from a rare alliance of the pharma and tech industries as well as past agency leaders, the U.S. Patent and Trademark Office (USPTO) has withdrawn a proposed new rule directed at Terminal Disclaimer...more
12/10/2024
/ Corporate Counsel ,
Life Sciences ,
Obviousness-Type Double Patenting (ODP) ,
Patent Applications ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Proposed Rules ,
Technology ,
Terminal Disclaimer ,
USPTO
When it comes to product development, the management of third-party intellectual property (IP) to ensure freedom to operate is of paramount importance. Drug development is no different. Imagine investing years of research,...more
According to a new report published this month by the San Diego Regional Economic Development Corporation (EDC) Research Bureau (the EDC Report), San Diego is building upon its long-standing reputation as a world-leading...more